| scholarly article | Q13442814 |
| P50 | author | Wolf Otto Bechstein | Q2588589 |
| Eric Van Cutsem | Q37068027 | ||
| Bernard Nordlinger | Q125194306 | ||
| P2093 | author name string | Peter M Schlag | |
| Werner Hohenberger | |||
| Peter Reichardt | |||
| Florian Lordick | |||
| Manfred P Lutz | |||
| Baktiar Hasan | |||
| Christoph Schuhmacher | |||
| Paul M Schneider | |||
| Katja Ott | |||
| Arnulf Hoelscher | |||
| Claus F Eisenberger | |||
| John Welch | |||
| Murielle E Mauer | |||
| Cornelie Haag | |||
| Jörg R Siewert | |||
| Stephan Gretschel | |||
| Hans Wilke | |||
| P2860 | cites work | Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 |
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data | Q33203756 | ||
| Cancer statistics, 2000. | Q33895772 | ||
| Cancer of the esophagogastric junction | Q34348338 | ||
| Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study | Q34754369 | ||
| Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis | Q37742318 | ||
| Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer G | Q40202553 | ||
| Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer | Q43273409 | ||
| Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate | Q44498080 | ||
| Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study | Q44603561 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| Pretherapeutic laparoscopic staging in advanced gastric carcinoma. | Q51447986 | ||
| Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. | Q53388029 | ||
| Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection | Q71725197 | ||
| Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer | Q73523681 | ||
| Outcome of patients with proximal gastric cancer depends on extent of resection and number of resected lymph nodes | Q73668827 | ||
| P433 | issue | 35 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| neoadjuvant chemotherapy | Q108855558 | ||
| P304 | page(s) | 5210-5218 | |
| P577 | publication date | 2010-11-08 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. | |
| P478 | volume | 28 |
| Q58693604 | A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy |
| Q37174037 | A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer |
| Q41741997 | A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer |
| Q53320199 | A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. |
| Q87073410 | A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival |
| Q33656736 | A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis |
| Q60936182 | A randomised controlled trial to assess whether prehabilitation improves fitness in patients undergoing neoadjuvant treatment prior to oesophagogastric cancer surgery: study protocol |
| Q41571695 | A study on comparison of overall survival and disease- free survival among gastric cancer patients treated with two adjuvant and neoadjuvant methods |
| Q26858776 | Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward |
| Q38364619 | Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach? |
| Q28088619 | Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review |
| Q38196738 | Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? |
| Q34326579 | Adjuvant therapy for gastric cancer: current and future directions |
| Q38751667 | Adjuvant therapy for locally advanced gastric cancer |
| Q38034225 | Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus |
| Q38077141 | Adjuvant therapy in gastric cancer: what is the optimal approach? |
| Q26774528 | Advanced gastric cancer: What we know and what we still have to learn |
| Q90609239 | Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy |
| Q90318996 | Advancements and challenges in treating advanced gastric cancer in the West |
| Q47292574 | After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients. |
| Q35163577 | An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer |
| Q38031884 | Angiogenesis-related agents in esophageal cancer |
| Q33597539 | Antitumor effects and the underlying mechanism of licochalcone A combined with 5-fluorouracil in gastric cancer cells |
| Q87173580 | Aortoenteric fistula at the site of esophagojejunostomy after laparoscopic total gastrectomy: report of a case |
| Q33728359 | Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer |
| Q38338980 | Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review |
| Q50921709 | BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer. |
| Q92557676 | COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis |
| Q58755544 | CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in re |
| Q37717708 | Can perioperative chemotherapy for advanced gastric cancer be recommended on the basis of current research? A critical analysis |
| Q90449717 | Chances, risks and limitations of neoadjuvant therapy in surgical oncology |
| Q37661271 | Changing Trends in Gastric Cancer Surgery |
| Q45753175 | Chemotherapy Alone is an Appropriate Preoperative Therapy for Locally Advanced Esophageal Cancer |
| Q35917089 | Chemotherapy for operable gastric cancer: current perspectives |
| Q33417749 | Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials |
| Q55714597 | Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. |
| Q38003583 | Clinical trials in gastric cancer and the future |
| Q34631121 | Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review |
| Q36967771 | Combination of preoperative platelet/lymphocyte and neutrophil/lymphocyte rates and tumor-related factors to predict lymph node metastasis in patients with gastric cancer |
| Q58799117 | Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis |
| Q39026949 | Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone |
| Q41512455 | Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database |
| Q28086772 | Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences |
| Q30248541 | Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer |
| Q91756528 | Comparison on Clinicopathological Features, Treatments and Prognosis between Proximal Gastric Cancer and Distal Gastric Cancer: A National Cancer Data Base Analysis |
| Q50215058 | Comprehensive Analysis of the Neutrophil-to-Lymphocyte Ratio for Preoperative Prognostic Prediction Nomogram in Gastric Cancer |
| Q30459126 | Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy |
| Q54457256 | Could a Feeding Jejunostomy be Integrated into a Standardized Preoperative Management of Oeso-gastric Junction Adenocarcinoma? |
| Q42083402 | Curative treatment in a patient with gastric cancer stage IV: a case report |
| Q26748744 | Current adjuvant treatment modalities for gastric cancer: From history to the future |
| Q90319007 | Current status of adjuvant chemotherapy for gastric cancer |
| Q55033047 | Customization of therapy for gastroesophageal adenocarcinoma patients. |
| Q36643077 | D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy |
| Q90433471 | Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group |
| Q45999575 | Diagnostic staging laparoscopy in gastric cancer treatment: A cost-effectiveness analysis. |
| Q56656007 | Diagnostik und Therapie des Magenkarzinoms |
| Q87926536 | Different regimens of perioperative chemotherapy for esophagogastric and gastric adenocarcinoma: does a triplet therapy with taxane generate a survival benefit? |
| Q37116949 | Different survival outcomes after curative R0-resection for Eastern Asian and European gastric cancer: Results from a propensity score matched analysis comparing a Korean and a German specialized center. |
| Q47614497 | Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma? |
| Q64284309 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction |
| Q49548232 | Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis |
| Q44316617 | Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer |
| Q36529266 | Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis |
| Q37697546 | Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer |
| Q37434552 | FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer |
| Q39497734 | Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor |
| Q92433609 | Five-year survival of Advanced Esophagogastric junction cancer with achieved by complete response preoperative S-1 + CDDP combination therapy and surgical resection |
| Q38630652 | Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression. |
| Q99622843 | Gastric cancer |
| Q42615450 | Gastric cancer: clinical aspects, epidemiology and molecular background |
| Q37828465 | Gastric cancer: surgery in 2011. |
| Q53207850 | Gastric cardia adenocarcinoma microRNA profiling in Chinese patients. |
| Q91741575 | Graded histologic response after neoadjuvant chemotherapy is an optimal criterion for treatment change in patients with locally advanced gastric cancer |
| Q36401587 | Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer |
| Q40487371 | Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLO |
| Q88316184 | Histopathological regression after taxane based neoadjuvant chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma |
| Q92241733 | How I treat gastric adenocarcinoma |
| Q49532535 | Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer |
| Q46837098 | Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. |
| Q53496643 | Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. |
| Q53096881 | Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. |
| Q42465120 | International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus |
| Q92841176 | Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines |
| Q39199654 | Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? |
| Q40707094 | Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: safety and short-term oncologic results |
| Q41898734 | Latest developments and emerging treatment options in the management of stomach cancer |
| Q38618861 | Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer |
| Q28082596 | Locally advanced gastroesophageal junction tumor: a treatment dilemma |
| Q38076028 | Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East |
| Q60301046 | Low periostin expression predicts poor survival in intestinal type gastric cancer patients |
| Q38493106 | Lymph node dissection for gastric cancer: a critical review. |
| Q38072886 | Management of localized gastric cancer |
| Q34326546 | Medical management of gastric cancer: a 2014 update |
| Q47312688 | Medical management of gastric cancer: a 2017 update |
| Q38184934 | Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. |
| Q38481127 | Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma |
| Q26799748 | Multimodal treatment of gastric cancer in the west: Where are we going? |
| Q92972956 | Multimodality management of locally advanced gastric cancer-the timing and extent of surgery |
| Q34340956 | Multimodality management of resectable gastric cancer: A review |
| Q26774283 | Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives |
| Q33978927 | Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). |
| Q37345859 | Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies |
| Q27016030 | Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward |
| Q31150068 | Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials |
| Q38090980 | Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy |
| Q48511305 | Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? |
| Q38410192 | Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials |
| Q38113822 | Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis |
| Q59075723 | Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center |
| Q42971706 | Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer |
| Q89992803 | Neoadjuvant therapy for esophageal cancer: Who, when, and what? |
| Q26781043 | Neoadjuvant therapy for gastric cancer: current evidence and future directions |
| Q26746147 | Neoadjuvant therapy for gastroesophageal adenocarcinoma |
| Q64060776 | Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling |
| Q48262613 | Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer |
| Q36993475 | Neoadjuvant treatment for gastric cancer |
| Q37187705 | New utility of an old marker: serum low-density lipoprotein predicts histopathological response of neoadjuvant chemotherapy in locally advanced gastric cancer |
| Q36144530 | Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients |
| Q57294866 | Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option |
| Q38220816 | Operable gastro-oesophageal junctional adenocarcinoma: Where to next? |
| Q93024218 | Optimal management of gastroesophageal junction cancer |
| Q38545533 | Optimal management of resectable gastric adenocarcinoma |
| Q36107240 | Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer |
| Q41495524 | Outcome of gastric cancer in the elderly: a population-based evaluation of the Munich Cancer Registry. |
| Q26851986 | Outcome reporting in neoadjuvant surgical trials: a systematic review of the literature and proposals for new standards |
| Q45806598 | Outcome, complications, and mortality of an intrathoracic anastomosis in esophageal cancer in patients without a preoperative selection with a risk score |
| Q93023155 | Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study |
| Q40922028 | Palliative surgery in visceral medicine. Exemplified by colorectal and gastric cancer |
| Q41952342 | Pathological complete response and long-term survival in a very elderly patient after neoadjuvant chemotherapy for locally advanced, unresectable gastric cancer. |
| Q49941215 | Patients Administered Neoadjuvant Chemotherapy Could be Enrolled into an Enhanced Recovery after Surgery Program for Locally Advanced Gastric Cancer |
| Q64064533 | Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions |
| Q24202957 | Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus |
| Q38748376 | Perioperative chemotherapy for resectable gastric cancer - what is the evidence? |
| Q38169894 | Perioperative chemotherapy in locally advanced gastric cancer. |
| Q35737764 | Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis |
| Q40305149 | Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival |
| Q38848598 | Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients. |
| Q47716404 | Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry |
| Q38134835 | Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care |
| Q33399537 | Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer |
| Q37580437 | Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma |
| Q45023889 | Population-based outcome of stage IA-IIA resected gastric adenocarcinoma: who should get adjuvant treatment? |
| Q91951298 | Postoperative complications and mobilisation following major abdominal surgery with vs. without fitness tracker-based feedback (EXPELLIARMUS): study protocol for a student-led multicentre randomised controlled trial (CHIR-Net SIGMA study group) |
| Q91906443 | Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis |
| Q58597627 | Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis |
| Q47236759 | Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer |
| Q38824375 | Potentially Curable Cancers of the Esophagus and Stomach. |
| Q42332601 | Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine. |
| Q64916251 | Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. |
| Q36555935 | Preoperative chemoradiotherapy for locally advanced gastric cancer |
| Q24187910 | Preoperative chemotherapy for resectable thoracic esophageal cancer |
| Q87559469 | Preoperative chemotherapy in gastric cancer: expanding the indications, limiting the overuse |
| Q85639453 | Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients |
| Q39393152 | Preoperative tumor restaging and resectability assessment of gastric cancers after chemotherapy: diagnostic accuracy of MDCT using new staging criteria. |
| Q40162858 | Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. |
| Q42049445 | Prognostic Significance of Preoperative and Postoperative Plasma Levels of Ghrelin in Gastric Cancer: 3-Year Survival Study |
| Q47104414 | Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection |
| Q37044761 | Prognostic factors for stage IV gastric cancer |
| Q87926502 | Prognostic impact of nodal status and therapeutic implications |
| Q37681788 | Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas |
| Q58743551 | Progress of preoperative and postoperative radiotherapy in gastric cancer |
| Q47393690 | Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications |
| Q38200031 | Prospective comparison of 3T MRI with diffusion-weighted imaging and MDCT for the preoperative TNM staging of gastric cancer |
| Q35336183 | Proteomic and metabolic prediction of response to therapy in gastric cancer |
| Q38051100 | Quality of care indicators for the surgical treatment of gastric cancer: a systematic review. |
| Q47549613 | Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. |
| Q35152370 | Radical gastrectomy with hepatoarterial catheter implantation for late-stage gastric cancer |
| Q26751327 | Recent developments and innovations in gastric cancer |
| Q35034753 | Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma |
| Q55690221 | Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. |
| Q51142736 | Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. |
| Q36611286 | Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. |
| Q36392301 | Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients |
| Q44910169 | Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection |
| Q38665539 | Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: a multi-institutional analysis. |
| Q50673503 | Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. |
| Q36400378 | Seom guidelines for the treatment of gastric cancer 2015. |
| Q48214260 | Short-term outcomes after laparoscopic versus open transhiatal resection of Siewert type II adenocarcinoma of the esophagogastric junction. |
| Q45054425 | Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction |
| Q36495346 | Staging laparoscopy improves treatment decision-making for advanced gastric cancer |
| Q90402831 | Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 g |
| Q41455900 | Surgery of gastric cancer and esophageal cancer: Does age matter? |
| Q35742852 | Surgical considerations in the treatment of gastric cancer |
| Q44228036 | Surgical indications for gastrectomy combined with distal or partial pancreatectomy in patients with gastric cancer |
| Q34962070 | Surgical management of gastric cancer: the East vs. West perspective |
| Q99583724 | Surgical outcomes and survival for T4 gastric cancer extending to the transverse colon |
| Q39737918 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. |
| Q89555538 | TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer |
| Q61795899 | The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis |
| Q50450374 | The Impact of Perioperative Red Blood Cell Transfusions on Long-Term Outcomes after Hepatectomy for Colorectal Liver Metastases. |
| Q53087621 | The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. |
| Q34082404 | The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine |
| Q49970732 | The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer |
| Q54969415 | The comparison of predictive factors regarding prognoses and invasion of thymic neuroendocrine tumors preoperatively and postoperatively. |
| Q40962026 | The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality |
| Q40359839 | The influence of neoadjuvant chemotherapy on gastric cancer patients' postoperative infectious complications: What is the negative role played by the intestinal barrier dysfunction? |
| Q64941276 | The postoperative lean body mass loss at one month leads to a poor survival in patients with locally advanced gastric cancer. |
| Q34678579 | The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. |
| Q58552952 | The role of different adjuvant therapies in locally advanced gastric adenocarcinoma |
| Q50996446 | The value of palliative gastrectomy in gastric cancer with distant metastasis. |
| Q89290547 | The ypT category does not impact overall survival in node negative gastric cancer |
| Q26778029 | Towards curative therapy in gastric cancer: Faraway, so close! |
| Q34137285 | Towards personalized perioperative treatment for advanced gastric cancer. |
| Q24602875 | Treatment of gastric cancer |
| Q45712888 | Treatment of gastric cancer beyond current guideline: state of the art |
| Q35060178 | Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients |
| Q34062470 | Trends in the surgical treatment of gastric adenocarcinoma |
| Q64226735 | Unnecessity of lymph node regression evaluation for predicting gastric adenocarcinoma outcome after neoadjuvant chemotherapy |
| Q34638268 | Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection |
| Q38594498 | Updated evidence on adjuvant treatments for gastric cancer |
| Q38120424 | Updates on surgical management of advanced gastric cancer: new evidence and trends. Insights from the First International Course on Upper Gastrointestinal Surgery--Varese (Italy), December 2, 2011. |
| Q45197627 | Validity of studies suggesting postsurgical chemotherapy for resectable gastric cancer: critical appraisal of randomised trials |
| Q38247980 | What make differences in the outcome of adjuvant treatments for resected gastric cancer? |
| Q38092435 | Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis |
| Q84617751 | [Advanced gastric cancer. Are there still indications for palliative surgical interventions?] |
| Q82732354 | [Current S3 guidelines on surgical treatment of gastric carcinoma] |
| Q82045726 | [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy] |
| Q82536787 | [Lymphadenectomy for malignancies of the upper gastrointestinal tract] |
| Q86168561 | [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management] |
| Q88216380 | [Palliative treatment of advanced gastric cancer from surgical point of view] |
| Q85914228 | [Surgical treatment of gastric carcinoma. German multicenter observational studies] |
| Q86578814 | [Treatment of gastric cancer] |
Search more.